C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2026)

C4 Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 27446000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 4.27% year-over-year to 27446000.0; the TTM figure through Mar 2026 stood at 105997000.0 (down 2.63% YoY), while the FY2025 annual figure was 104994000.0, changed 0.31% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 27446000.0, down from 20365000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 17716000.0 in Q2 2024, with the low at 128670000.0 in Q2 2022.
• The 5-year median for Income from Continuing Operations is 31620000.0 (2022), against an average of 35268470.59.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 469.84% in 2022, then jumped 72.08% in 2023.
• C4 Therapeutics' Income from Continuing Operations stood at 37185000.0 in 2022, then grew by 6.53% to 34757000.0 in 2023, then grew by 0.53% to 34573000.0 in 2024, then surged by 41.1% to 20365000.0 in 2025, then tumbled by 34.77% to 27446000.0 in 2026.
• Business Quant data shows CCCC's Income from Continuing Operations at 27446000.0 in Q1 2026, 20365000.0 in Q4 2025, and 32166000.0 in Q3 2025.